Nicholas DeVito, Assistant Professor of Medicine at the Division of Medical Oncology at Duke University, shared a post on LinkedIn:
“Our first-line immunotherapy (botensilimab/balstilimab) trial for advanced/metastatic colorectal cancer without liver, bone, or brain metastasis is still enrolling!
This trial is supported by Gateway for Cancer Research, Duke CRUSH CRC, and patient philanthropy.
Learn more about the BBOpCo trial here.”